<qa>  What is the SYMPTOMATIC DESPITE THERAPY?A COMPASSIONATE ACCESS PROTOCOL TO ASSESS THE SAFETY OF XOLAIRTM OMALIZUMAB IN PATIENTS 6 YEARS OLD WITH SEVERE ALLERGIC ASTHMA WHO REMAIN SYMPTOMATIC DESPITE OPTIMAL THERAPY: 